RVNC - Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition | Benzinga
AbbVie Inc (NYSE:ABBV) remains confident in Botox’s resilience in the aesthetics market, assured by its ability to sustain a dominant 68% share, as highlighted by Chief Commercial Officer Jeffrey Stewart during the J.P. Morgan healthcare conference.
In December, Consumer advocacy group Public Citizen filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to Botox and similar injections.
These treatments, leveraging botulinum toxins to target specific muscles and erase wrinkles, currently carry a ‘black box’ ...